Targeting the MYCN effector, FAK, in neuroblastoma.
Davidoff
Andrew M
AM
St. Jude Children’s Research Hospital, Memphis, TN, USA. Andrew.davidoff@stjude.org
D000814:Aniline Compounds / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000188:drug therapy / Q000201:enzymology*; D009687:Nuclear Proteins / Q000378:metabolism*; D015513:Oncogene Proteins / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
C539551:1,2,4,5-benzenetetraamine; D000814:Aniline Compounds; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D051416:Focal Adhesion Protein-Tyrosine Kinases